SCHEMBL1146142

SCHEMBL1146142

CSc1ccccc1CO

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
APOBEC3G Q9HC16 1/20 0.67
CHRM2 P08172 1/20 0.48
SLC6A4 P31645 7/20 0.45
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
LMNA P02545 3/20 0.41
PDCD1 Q15116 1/20 0.41
CD274 Q9NZQ7 1/20 0.41
KMT2A Q03164 2/20 0.41
GAA P10253 1/20 0.41
SLC6A2 P23975 4/20 0.40
SLC6A3 Q01959 1/20 0.39
MEN1 O00255 1/20 0.37
KDM4E B2RXH2 1/20 0.37
CHRM4 P08173 1/20 0.37
HTR7 P34969 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9763265 0.82 CHRM2 (0.46) APOBEC3GCHRM2SLC6A4ALDH1A1MAPT
SCHEMBL4901824 0.82 APOBEC3G (0.75) APOBEC3GCHRM2SLC6A4LMNAPDCD1
SCHEMBL16957698 0.80 PDCD1 (0.50) APOBEC3GCHRM2SLC6A4ALDH1A1MAPT
SCHEMBL7262305 0.80 APOBEC3G (1.00) APOBEC3GSLC6A4MAPTL3MBTL1LMNA
SCHEMBL4442278 0.80 APOBEC3G (0.73) APOBEC3GSLC6A4ALDH1A1LMNASLC6A2
SCHEMBL27460927 0.80 SLC6A4 (0.65) APOBEC3GSLC6A4KMT2ASLC6A2SLC6A3
SCHEMBL16960146 0.79 APOBEC3G (0.47) APOBEC3GCHRM2SLC6A4ALDH1A1MAPT
SCHEMBL16951622 0.79 APOBEC3G (0.47) APOBEC3GCHRM2SLC6A4ALDH1A1MAPT
SCHEMBL8481321 0.78 CHRM2 (0.50) APOBEC3GCHRM2SLC6A4ALDH1A1MAPT
SCHEMBL7495159 0.77 CHRM2 (0.46) APOBEC3GCHRM2SLC6A4ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112204035-A Substituted 3,4,12,12 a-tetrahydro-1 n1- [1,4] oxazino [3,4-c ] pyrido [2,1-f ] [1,2,4] triazine-6, 8-diones, pharmaceutical compositions, methods of production and uses thereof 亚历山大·瓦西里耶维奇·伊瓦切恩科 2021-01-08 CN claimed
WO-2020226532-A1 SUBSTITUTED 3,4,12,12A-TETRAHYDRO-1H-[1,4]OXAZINO[3,4-C]PYRIDO[2,1-F][1,2,4]TRIAZINE-6,8-DIONE, PHARMACEUTICAL COMPOSITION, AND METHODS FOR PREPARING AND USING SAME ИВАЩЕНКО, Александр Васильевич 2020-11-12 WO claimed
CN-115151553-B Boric acid derivatives 首药控股(北京)股份有限公司 2025-06-13 CN disclosed
EP-4328229-A2 SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF Genfleet Therapeutics (Shanghai) Inc. (CN) 2024-02-28 EP disclosed
WO-2023210623-A1 HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME 株式会社エス・ディー・エス バイオテック 2023-11-02 WO disclosed
WO-2023141852-A1 CDK2 INHIBITORS, PREPARATION METHOD THEREFOR AND USE THEREOF 益方生物科技(上海)股份有限公司 2023-08-03 WO disclosed
US-20230167131-A1 HETEROCYCLIC PAD4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2023-06-01 US disclosed
CN-115151553-A Boronic acid derivatives 首药控股(北京)股份有限公司 2022-10-04 CN disclosed
CN-111517902-B Aerobic oxidation system containing sulfinic acid, sulfonic acid or derivatives thereof and photo-oxidation promoting method thereof 清华大学 2022-06-14 CN disclosed
US-20210338696-A1 Lipid Disulfide Prodrugs and Uses Related Thereto UNIV EMORY (US) 2021-11-04 US disclosed
WO-2021143923-A1 BORONIC ACID DERIVATIVES 首药控股(北京)股份有限公司 2021-07-22 WO disclosed
EP-0618900-B1 SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS KNOLL AG (DE) 1997-03-12 EP disclosed
EP-0510526-B1 Use of sulfonamides as drug and new sulfonamides HOFFMANN LA ROCHE (CH) 1996-12-04 EP disclosed
WO-1996024584-A1 2,3-SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-08-15 WO disclosed
US-5519034-A ANALGESICS THE BOOTS COMPANY PLC (GB) 1996-05-21 US disclosed
EP-0618900-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS. BOOTS CO PLC (GB) 1994-10-12 EP disclosed
US-5270313-A Treatment of circulatory disorders HOFFMANN-LA ROCHE INC. (US) 1993-12-14 US disclosed
WO-1993013073-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS THE BOOTS COMPANY PLC (GB) 1993-07-08 WO disclosed
EP-0510526-A1 Use of sulfonamides as drug and new sulfonamides F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT (CH) 1992-10-28 EP disclosed
EP-0257768-A1 2-Isopropyl-2-phenyl-5-(N-methyl-2-phenylethylamino)-valeronitrile derivatives and processes for their preparation SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu (CS) 1988-03-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210338696-A1 Lipid Disulfide Prodrugs and Uses Related Thereto SMPD1, SGMS1, GSTO1 APOBEC3G 1742/4885CHRM2 4749/4885SLC6A4 1311/4885
US-20230167131-A1 HETEROCYCLIC PAD4 INHIBITORS PADI4, PADI2, PADI6 APOBEC3G 720/4885CHRM2 4262/4885SLC6A4 2383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.